N4 Pharma PLC Work Programme Update (5599S)
15 July 2022 - 4:00PM
UK Regulatory
TIDMN4P
RNS Number : 5599S
N4 Pharma PLC
15 July 2022
15 July 2022
N4 Pharma Plc
("N4 Pharma" or the "Company")
Work Programme Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to announce a further update on its recent
pre-clinical study with TNF alpha.
On 13 June 2022 the Company provided an update that the
Medicines Discovery Catapult study showed clear tumour suppression
with 10ug of the TNF-alpha loaded onto Nuvec(R) which was a lower
dose than used in the earlier studies.
Biochemical analysis of blood and tissue samples has now been
completed. Testing confirmed that treatment with 10ug TNF-alpha
loaded onto Nuvec(R) resulted in an increase in circulating plasma
TNF-alpha levels.
Analysis also indicated that tissues including the liver and the
tumour cells may have been responsible for the transfection with
the TNF plasmid and subsequent release of TNF-alpha into the
circulation to suppress the tumour.
This study provides further data to better understand the
mechanism that produced the tumour suppression. This data indicates
the most appropriate use of Nuvec(R) in the oncology field will
likely be to combine it with one or more nucleic acids alongside a
targeting ligand to allow specific cancer cells to be targeted.
The posters resulting from the original oncology studies
undertaken by Nanomerics have been presented at the CRS Annual
Meeting in Montreal, Canada and are available to view on the
Company's website.
Nigel Theobald, Chief Executive Officer of the Company,
commented :
"We continue to make good progress in understanding how Nuvec
(R) can be used in the oncology space and this work, combined with
the potential opening up of the siRNA market and the early data
coming from UQ on their oral work, gives us a lot of material to
further focus our route to commercial success.
"We will provide a further update of this along with our interim
results."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 which has been
incorporated into UK law by the European Union (Withdrawal) Act
2018.
Enquiries:
N4 Pharma Plc Via IFC Advisory
Nigel Theobald, CEO
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: + 44 (0)20 3470
Nominated Adviser and Joint Broker 0470
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
IFC Advisory Limited Tel: +44 (0)20 3934
Financial PR 6630
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDQZLFFLDLFBBZ
(END) Dow Jones Newswires
July 15, 2022 02:00 ET (06:00 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2024 to May 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From May 2023 to May 2024